Candidate plasma biomarkers for predicting ascending aortic aneurysm in bicuspid aortic valve disease

Oliver J. Harrison 1,2*, Felino Cagampang 1, Sunil K. Ohri 2, Christopher Torrens 1, Kareem Salhiyyah 2, Amit Modi 3, Narain Moorjani 4, Anthony D. Whetton 5,6 and Paul A. Townsend 5,6

Abstract

Background: Bicuspid aortic valve (BAV) disease is the most common congenital cardiac abnormality affecting 1–2% of the population and is associated with a significantly increased risk of ascending aortic aneurysm. However, predicting which patients will develop aneurysms remains a challenge. This pilot study aimed to identify candidate plasma biomarkers for monitoring ascending aortic diameter and predicting risk of future aneurysm in BAV patients.

Methods: Plasma samples were collected pre-operatively from BAV patients undergoing aortic valve surgery. Maximum ascending aortic diameter was measured on pre-operative transoesophageal echocardiography. Maximum diameter ≥45 mm was classified as aneurysmal. Sequential Window Acquisition of all Theoretical Mass Spectra (SWATH-MS), an advanced mass spectrometry technique, was used to identify and quantify all proteins within the samples. Protein abundance and aortic diameter were correlated using logistic regression. Levene’s test was used to identify proteins demonstrating low abundance variability in the aneurysmal patients (consistent expression in disease), and high variability in the non-aneurysmal patients (differential expression between ‘at risk’ and not ‘at risk’ patients).

Results: Fifteen plasma samples were collected (seven non-aneurysmal and 8 aneurysmal BAV patients). The mean age of the patients was 55.5 years and the majority were female (10/15, 67%). Four proteins (haemoglobin subunits alpha, beta and delta and mannann-binding lectin serine protease) correlated significantly with maximal ascending aortic diameter (p < 0.05, r = 0.5–0.6). Five plasma proteins demonstrated significantly lower variability in the aneurysmal group and may indicate increased risk of aneurysm in non-aneurysmal patients (DNA-dependent protein kinase catalytic subunit, lumican, tetranectin, gelsolin and cartilage acidic protein 1). A further 7 proteins were identified only in the aneurysmal group (matrin-3, glucose-6-phosphate isomerase, coactosin-like protein, peptidyl-prolyl cis-trans isomerase A, golgin subfamily B member 1, myeloperoxidase and 2′-deoxynucleoside 5′-phosphate N-hydrolase 1).

Conclusions: This study is the first to identify candidate plasma biomarkers for predicting aortic diameter and risk of future aneurysm in BAV patients. It provides valuable pilot data and proof of principle that could be used to design a large-scale prospective investigation. Ultimately, a more affordable ‘off-the-shelf’ follow-on blood assay could then be developed in place of SWATH-MS, for use in the healthcare setting.

Keywords: Bicuspid aortic valve, Ascending aortic aneurysm, Plasma biomarker, Risk prediction
Background
Bicuspid aortic valve (BAV) disease is the most common congenital cardiac malformation affecting 1–2% of the population [1, 2]. BAV occurs when the aortic valve forms with just two leaflets (or cusps), rather than the normal three (tricuspid aortic valve; TAV). Although between 30 and 80% of patients with BAV disease will develop clinically significant enlargement of the ascending aorta, predictors of aortic dilation are lacking [3, 4]. The consequences of undiagnosed or rapidly progressive aneurysm can be severe, with rupture and dissection frequently being fatal. There is ongoing controversy regarding optimal timing of ascending aortic surgery for patients with BAV disease [5, 6]. Current guidelines are limited to measurement of ascending aortic diameter and the extent of aortic valve disease when planning surgery for aortic aneurysm in BAV patients [7]. An ability to predict which BAV patients will develop ascending aortic aneurysm would allow better individualisation of treatment and help prevent the potentially catastrophic complications of rupture and dissection.

A biomarker may be defined as a measurable gene, protein, cell or metabolic by-product that represents a process in a defined biological system or disease state [8, 9]. One or a combination of biomarkers may be measured to give information about risk, presence and progress of a particular disease. Several studies have attempted to identify biomarkers in BAV aortopathy, however few have investigated blood biomarkers. Matrix metalloproteinases (MMPs) are implicated in the pathogenesis of BAV aortopathy, and the expression of MMP-2, MMP-8 and MMP-9 has been demonstrated to correlate with ascending aortic diameter [10–14]. Similarly, asymmetric dimethylarginine (ADMA; a nitric oxide synthase inhibitor), alpha-1-antitrypsin (α1AT; an abundant protease inhibitor) and more recently circulating endothelial microparticles (EMP), have all been shown to differ in expression between non-aneurysmal and aneurysmal BAV patients [12, 13, 15]. Currently however, measurement of the ascending aortic diameter is the only method widely used to monitor aortopathy in BAV patients [16].

Sequential Window Acquisition of all THeoretical Mass Spectra (SWATH-MS) is one of the most recent advances in protein quantification technology, combining the advantages of the shotgun (high throughput) and selected reaction monitoring (high reproducibility and consistency) mass spectrometry techniques [17]. In essence, it allows a complete recording of all fragment ions of the detectable peptide precursors present in a biological sample, and thus is ideally suited to biomarker discovery. However, to the best of our knowledge, the technique has never before been used for the purpose of biomarker discovery in BAV-associated aneurysms.

Discovery of novel biomarkers for detection and monitoring of aneurysms in BAV disease has a number of potential benefits. Firstly, a suitable biomarker could be monitored as an indicator of aortic diameter in preference to repeated imaging, particularly computerised tomography, which carries a radiation risk. Secondly, biomarkers that predict risk of future aneurysm in BAV patients would help prevent catastrophic complications and allow individualisation when planning aortic surgery. The question asked recently by Sievers et al. is extremely important; in the young patient requiring aortic valve replacement for severe aortic stenosis, with an ascending aortic diameter at the higher end of normal; should it be replaced? [18] There is a pressing need for biomarkers to facilitate a more patient-centred approach to managing BAV aortopathy. We hypothesise that a subpopulation of BAV patients without aortic aneurysms exhibit a biomarker profile that indicates they will develop ascending aortic aneurysm in future. Therefore, the two aims of this study were to correlate plasma protein concentrations with ascending aortic diameter to identify biomarkers which could be used to estimate ascending aortic diameter in BAV patients. Secondly, to identify biomarkers which are homogenously expressed in the aneurysmal BAV group but differentially expressed in non-aneurysmal BAV patients, and may signify increased risk of future aneurysm. Here we show that a number of candidate predictors for aortic diameter were identified and these may help stratify the future risk of aneurysm in BAV patients. Our study, albeit small, provides proof of principle data that offers confidence in the potential design of a larger, prospective investigation of candidate BAV biomarkers.

Methods
Ethical approval and sample collection
This study complied with the declaration of Helsinki. Ethical approval was granted by Hampshire B NRES committee south central (REC Ref: 11/SC/0258). The local sponsor was University Hospital Southampton R&D Department (Protocol Ref: RH2 CAR 0392). Informed consent was obtained from patients admitted electively to the University Hospital Southampton, UK for aortic valve replacement and/or ascending aortic replacement. Patients with mitral valve disease (greater than mild), atherosclerosis of the ascending aorta (either on pre-operative imaging or observed intraoperatively), infective endocarditis, known genetic conditions (such as Marfan Syndrome), and those aged under 18 or over 80 were excluded from the study. Demographic information, past medical history, echocardiography data and blood results were collected. In the anaesthetic room, all patients underwent transoesophageal echocardiography (TOE) as part of the routine theatre practice. From these
images, ascending aortic measurements were obtained. Aneurysm of the ascending aorta was defined as diameter ≥ 45 mm. Aortic valve morphology was defined intraoperatively by the surgeon according to the Sievers classification [19]. Fifteen plasma samples were collected (seven from non-aneurysmal and eight from aneurysmal BAV patients). Shortly after the induction of anaesthesia 4 mL of whole blood was taken from the central venous cannula immediately after insertion. The blood was collected following our standard operating procedure (SOP) in an EDTA containing tube and immediately placed on ice before being centrifuged at 1500 rpm for 10 min at 4°C. The plasma layer was aliquoted into microtubes and stored at -80°C until use.

Plasma samples were subject to SWATH-MS according to the standard operating procedures of the Stoller Biomarker Discovery Centre, Manchester, UK (see Additional file 1). In brief, major plasma proteins were removed by immunodepletion following which protein concentration was measured in each sample. Samples were then digested and dried overnight before processing in a SCIEX TripleTOF 6600 variable window mass spectrometer with a 120 min run time. The presence and abundance of plasma proteins was quantified using protein spectral libraries and SWATH-MS maps.

Statistical analysis
Statistical analysis was performed using IBM SPSS Statistics (Version 22.0). Linear regression analysis was performed to detect significant correlations between maximum aortic diameter and plasma protein levels. Levene’s test was used to identify plasma proteins demonstrating significant differences in equality of variance between non-aneurysmal and aneurysmal groups. Levene’s test assesses the probability that a difference in the variability between two populations has occurred by chance. Where Levene’s test was significantly different, scatter plots were generated and proteins displaying low variability in the aneurysmal group (and high variability in the non-aneurysmal group) were identified as potential aortopathy risk predictors. An ‘at risk’ cut-off point for candidate biomarker expression in the non-aneurysmal patients was established at 2 standard deviations above or below the mean expression in the aneurysmal group. Where candidate markers were expressed in non-aneurysmal patients at such a level, these patients were deemed hypothetically ‘at risk’. p < 0.05 was taken as statistically significant.

Results
Fifteen plasma samples were collected (seven non-aneurysmal and eight aneurysmal BAV patients). The mean age of the patients was 55.5 years and the majority of patients were female (10/15; 67%, Table 1). The groups were equally matched, except none of the aneurysmal patients were prescribed statins and their pre-operative haemoglobin values were higher. Overall 826 proteins were identified across the 15 samples.

Plasma biomarkers as predictors of aortic diameter in BAV patients
Linear regression analysis of plasma proteins revealed four significant (p < 0.05) predictors of maximum aortic diameter in BAV patients (Table 2). Haemoglobin subunits alpha, beta and delta correlated positively with increasing maximum ascending aortic diameter, and Mannan-binding lectin serine protease correlated negatively (Fig. 1). All four proteins demonstrated moderate correlation (r = 0.5 to 0.6). Of note, the patient’s pre-operative serum haemoglobin did not correlate significantly with the maximum aortic diameter (p = 0.279).

Plasma biomarkers to predict risk of future aortopathy
In order to identify potential plasma protein biomarkers predictive of future aneurysm risk, subgroup analysis was performed on the BAV non-aneurysmal group. Five candidate plasma protein markers exhibiting low variance in the aneurysmal group but high variance in the non-aneurysmal group were identified as potential predictors of future aortopathy (Fig. 2). These were DNA-dependent protein kinase catalytic subunit, lumican, tetrancetin, gelsolin and cartilage acidic protein 1.

In addition, seven proteins were identified in the plasma from all patients with aneurysmal aortas but only identified in a subset of the non-aneurysmal group. These were matrin-3, glucose-6-phosphate isomerase, coactosin-like protein, peptidyl-prolyl cis-trans isomerase A, golgin subfamily B member 1, myeloperoxidase and 2′-deoxynucleoside 5′-phosphate N-hydrolase 1. Table 3 summarises the plasma proteins implicated above.

Discussion
The two main findings of this study are that four plasma proteins were identified as potential biomarkers for monitoring maximum aortic diameter in BAV patients, and 12 plasma proteins were identified as potential indicators for future aneurysm risk in BAV patients with non-aneurysmal aortas.

The advantage of SWATH-MS is that all proteins within a plasma sample can be detected and quantified, raising the possibility of discovering previously unknown relationships between these biomarkers and ascending aortic diameter in BAV patients. This study identified four unique plasma biomarkers that correlated significantly with maximum ascending aortic diameter in BAV patients. Previous studies have identified plasma biomarkers that correlate with aortic dimension in BAV disease. Tzemos et al. found MMP-2 levels correlated...
significantly with ascending aortic diameter, findings that are supported by the more recent work of Wang et al. [11, 14]. However, Abaci et al. found no correlation between MMP-2 and ascending aortic diameter [20]. In the present study, MMP-9 and 14 were elevated in the aneurysmal group but this was not statistically significant ($p = 0.767$ and $p = 0.242$ respectively). Drapisz et al. found a positive correlation between ADMA (eNOS inhibitor) and aortic annulus diameter ($r = 0.4$, $p = 0.043$) and Kilickesmez et al. demonstrated a significantly negative correlation between ascending aortic diameter and α1-antitrypsin level ($r = -0.300$, $p = 0.006$) [12, 13].

In this study, haemoglobin subunits alpha, beta and delta were found to correlate significantly with ascending aortic diameter in BAV patients. In adults, two alpha and two beta subunits combine to form one haemoglobin A molecule (HbA), which comprises approximately 97% of circulating haemoglobin. Combination of two alpha and two delta subunits forms haemoglobin A2, which together with fetal haemoglobin (HbF) makes up the remaining 3% of circulating haemoglobin [21].

Supporting these findings pre-operative serum haemoglobin (Hb) was significantly increased in the aneurysmal group versus non-aneurysmal but did not correlate significantly with maximum aortic diameter. This is a novel observation as to the best of our knowledge, there are no previous reports of this association in the literature. In abdominal aortic aneurysms (AAA) however, trapping of

### Table 1 Patient demographics

| Demographic                          | Non-aneurysmal (n = 7) | Aneurysmal (n = 8) | p-value |
|--------------------------------------|------------------------|-------------------|---------|
| Mean age (years)                     | 59.3 ± 13.3            | 51.8 ± 10.4       | 0.24    |
| Gender (n)                           |                        |                   |         |
| Male                                 | 3                      | 2                 | 0.32    |
| Female                               | 4                      | 6                 |         |
| Mean body mass index (kg/m$^2$)      | 29.9 ± 5.0             | 29.7 ± 5.1        | 0.02    |
| Mean maximum ascending aortic diameter (mm) | 40.6 ± 2.6            | 53.4 ± 5         | < 0.001 |
| Mean blood pressure (mmHg)           |                        |                   |         |
| Systolic                             | 137 ± 15.6             | 133 ± 16.3        | 0.61    |
| Diastolic                            | 73 ± 10.4              | 76 ± 11.1         | 0.57    |
| Smoking status (n)                   |                        |                   | 0.35    |
| Non-smoker                           | 5                      | 3                 |         |
| Ex-smoker                            | 2                      | 4                 |         |
| Current smoker                       | 0                      | 1                 |         |
| Type 2 diabetes (n)                  | 2                      | 1                 | 0.57    |
| Medications (n patients taking)      |                        |                   |         |
| ACE inhibitor                        | 2                      | 1                 | 0.57    |
| ß-blocker                            | 3                      | 2                 | 0.61    |
| Angiotensin Receptor Blocker         | 1                      | 0                 | 0.47    |
| Calcium Channel Blocker              | 1                      | 0                 | 0.47    |
| Statin                               | 4                      | 0                 | 0.03    |
| Aortic valve disease (n)             |                        |                   | 0.33    |
| Normal                               | 0                      | 0                 |         |
| Stenosis                             | 3                      | 1                 |         |
| Mild                                 | 0                      | 0                 |         |
| Mild                                 | 0                      | 0                 |         |
| Severe                               | 5                      | 6                 |         |
| Regurgitation                        | 2                      | 2                 |         |
| Mild                                 | 1                      | 3                 |         |
| Mod                                  | 1                      | 1                 |         |
| Severe                               | 2                      | 3                 |         |
| Mixed                                | 2                      | 5                 |         |
| Left ventricular ejection fraction (%) |            |                   | 0.47    |
| 45–70%                               | 7                      | 6                 |         |
| 35–44%                               | 0                      | 0                 |         |
| < 35%                                | 0                      | 0                 |         |
| Unknown                              | 0                      | 2                 |         |
| Mean preoperative blood results      |                        |                   |         |
| Haemoglobin (g/dl)                   | 138 ± 15               | 155 ± 15          | 0.047   |
| White cell count ($\times 10^{9}/l$) | 6.9 ± 1.8              | 8.7 ± 2.9         | 0.17    |
| Platelet count ($\times 10^{9}/l$)   | 226 ± 38               | 235 ± 38          | 0.65    |
| Urea (mmol/l)                        | 5.1 ± 1.6              | 4.7 ± 1.1         | 0.58    |

### Table 2 Significant predictors of maximum aortic diameter in BAV patients

| Plasma Protein                        | Pearson coefficient ($r$) | P-value | Gradient (m) | y-intercept (c) |
|---------------------------------------|---------------------------|---------|--------------|-----------------|
| Haemoglobin subunit beta              | 0.576                     | 0.025   | 0.410        | 0.066           |
| Haemoglobin subunit delta             | 0.558                     | 0.030   | 0.670        | -2.552          |
| Mannan-binding lectin serine protease | -0.552                    | 0.033   | -0.679       | 11.745          |

Mean values are given ± standard deviation. P-values are given for independent samples t-tests between the study groups. Significant p-values ($p < 0.05$) are highlighted in bold.
erythrocytes within areas of intraluminal thrombus may lead to haemolysis and subsequent release of Hb, heme and iron, which liberates reactive oxygen species (ROS) [22]. Erythrocytes and heme deposits are also phagocytosed by immune cells in the aortic wall [23]. Nevertheless, intraluminal thrombus is not commonly associated with BAV ascending aortic aneurysms and inflammation is classically absent [24, 25]. The lack of any previous reports of these observations requires further investigation and validation in a larger patient cohort.

A major goal in the treatment of BAV aortopathy is developing a method of predicting which patients will develop aneurysms. To date, only one study has attempted to do this by subdividing BAV patients with non-aneurysmal aortas based on risk of future aortopathy but using aortic tissue samples instead of blood biomarkers. Grewal et al. quantified an array of cellular markers in ascending aortic tissue samples from aneurysmal and non-aneurysmal BAV and TAV patients [26]. TGF-β and pSmad2 (markers of vascular remodelling) were significantly reduced in a proportion of the non-aneurysmal BAV group versus the other non-aneurysmal patients and the aneurysmal BAV group. The study concluded that a subgroup of BAV patients with non-aneurysmal aortas appear to have more active remodelling than others, which could represent susceptibility to developing aneurysm. To our knowledge, the paper by Grewal et al. is the first to attempt to subdivide non-aneurysmal BAV patients on the basis of susceptibility to developing aneurysm using biomarkers. Whilst it did not employ a plasma biomarker, which would be more practical in clinical practice, it set precedence for the future direction in detecting and preventing BAV aortopathy in susceptible individuals.

The present study is the first to utilise SWATH-MS to quantify all detectable proteins in blood plasma samples and identify potential biomarkers which may predict ‘at risk’ non-aneurysmal BAV patients. The principle advantage of blood over a tissue biomarker is that plasma samples are more easily obtainable, in comparison to ascending aortic tissue, which is less practical. Therefore, a result can be obtained from a blood test and a treatment plan implemented long before aneurysm develops. Twelve potential plasma biomarkers were identified. Of note, the ‘at risk’ patients demonstrated increased DNA-dependent protein kinase catalytic subunit, a protein associated with DNA damage, which may reflect the increased remodelling and vascular smooth muscle cell (VSMC) apoptosis occurring in BAV aortopathy. Similarly, down regulation of two key extracellular matrix (ECM) and VSMC cytoskeletal assembly proteins lumican and gelsolin were also observed in the ‘at risk’ profile. This is concurrent with accelerated ECM degradation and VSMC loss observed in BAV aortopathy [27, 28]. Therefore, these
biomarkers may reflect underlying pathological processes occurring in the ascending aorta and could represent entities with which to predict future aortopathy in BAV patients. A summary diagram of the key findings of this study can be found in Fig. 3.

A major limitation of this pilot study was not validating candidate biomarkers through follow-up of changes in ascending aortic diameter of the non-aneurysmal patients over time. This was not possible within the time scale of this study but should be included in the design of a future prospective validation investigation. Furthermore, in concluding that our candidate biomarkers may predict future aneurysm based on similar expression to aneurysmal patients, our assumption was that expression of the biomarkers remains constant. However, we cannot exclude the possibility that expression may vary over time and a validation study is required to confirm expression stability. Another limitation of this study was the small sample size. The main reason for this is the time taken to perform detailed informatics analysis of the data generated is considerable, therefore large sample numbers were not feasible within the time scale of this study. With small sample numbers, we cannot exclude the possibility that differences in the patient’s demographics (e.g. statin use and valve morphology) may have influenced the differences in protein expression described in this study. Furthermore, we were unable to correlate the plasma findings in paired tissue samples, although this is a subject of ongoing investigation. In addition, TAV control groups would have proved useful to ensure that the proteins identified were indeed unique to BAV aortopathy. However, investigation of TAV

Fig. 2 Scatter plots of candidate plasma biomarkers for predicting risk of aortopathy in non-aneurysmal BAV patients. Horizontal lines at 4.5 cm indicate the study’s division between non-aneurysmal and aneurysmal ascending aortic diameter. Vertical lines indicate mean expression in the aneurysmal group ± 2 standard deviations. Blue area = aneurysmal BAV cohort expressions up to mean ± 2 standard deviation; red area = hypothetically ‘at risk’ non-aneurysmal BAV patients; and green area = hypothetically not ‘at risk’ non-aneurysmal patients. Protein expression is given as log2 SWATH-MS abundance.
aneurysms was not the focus of this study, and the biomarkers identified may still differentiate ‘at risk’ BAV patients regardless of their presence in TAV patients. Finally, this study did not use correction for multiple testing, despite identifying a large number of candidate biomarkers. Whilst this has the potential to introduce falsely positive biomarkers, the priority of this study was to identify all potential biomarkers for future investigation, rather than excluding those with lower potential value.

Table 3 Candidate plasma biomarkers for predicting risk of aneurysm in BAV patients with non-aneurysmal aortas

| Protein Name                                 | Uniprot ID | Function                                                                 | Up- or downregulated |
|----------------------------------------------|------------|--------------------------------------------------------------------------|----------------------|
| DNA-dependent protein kinase catalytic subunit | P78527     | Serine/threonine-protein kinase, molecular sensor for DNA damage.        | Up                   |
| Lumican                                      | P51884     | Collagen fibril organization, epithelial cell migration and tissue repair.| Down                 |
| Tetranectin                                  | P05452     | Binds plasminogen and isolated kringel 4.                                 | Down                 |
| Gelsolin                                     | P06396     | Key regulator of actin filament assembly and disassembly.                 | Down                 |
| Cartilage acidic protein 1                   | Q9NQ79     | Upregulated by BMP4 in mesenchymal stem cells undergoing chondrogenic differentiation. | Down                 |
| Matrin-3                                     | P43243     | Transcription and interaction with other nuclear matrix proteins to form the internal fibrogranular network. | N/A                  |
| Glucose-6-phosphate isomerase                | P06744     | Glycolytic enzyme and angiogenic factor (AMF) that stimulates endothelial cell motility. | N/A                  |
| Coactasin-like protein                       | Q14019     | Binds to F-actin in a calcium-independent manner.                         | N/A                  |
| Peptidyl-prolyl cis-trans isomerase A         | P62937     | Accelerates the folding of proteins.                                      | N/A                  |
| Myeloperoxidase                              | P05164     | Produces hypochlorous acid (HOCl) used by the neutrophils to kill bacteria and other pathogens. | N/A                  |
| Golgin subfamily B member 1                  | Q14789     | Forms intercisternal cross-bridges of the Golgi complex.                  | N/A                  |
| 2′-deoxynucleoside 5′-phosphate N-hydrolase 1| O43598     | Catalyses cleavage of the N-glycosidic bond of deoxyribonucleoside 5′-monophosphates. | N/A                  |

Biomarker name, Uniprot ID, function and direction of change are given

*Direction of change in plasma biomarker that indicates a patient may be at risk of future aortopathy. ‘N/A’ (not applicable) indicates that presence of the protein in plasma alone may indicate risk of future aortopathy.

Fig. 3 Summary diagram of the key findings in this study. Red dots represent plasma biomarkers which may be associated with an increased risk of aneurysm formation (red box). Blue dots represent plasma biomarkers which predict aneurysm diameter (blue box).
Conclusions
This study identified a number of candidate predictors for aortic diameter and future risk of aneurysm in BAV patients. It provides valuable data and proof of principle that could be used to design a large scale prospective investigation of several hundred BAV patients. Plasma levels of candidate biomarkers need to be quantified in a large population of BAV patients and matched with changes in ascending aortic diameter from serial follow-up imaging, allowing direct correlation with disease progression. Ultimately, a more affordable ‘off-the-shelf’ follow-on blood assay could then be developed in place of SWATH-MS for use in the healthcare setting.

Additional file

Additional file 1: Supplementary methods. (DOCX 25 kb)

Acknowledgements
The authors would like to acknowledge the contribution of Dr. Julie Brazzati, Laura Farrell and Rachel Reed at the Stoller Biomarker Discovery Centre, Manchester, UK for processing the plasma samples, and Dr. David Lee who analysed the SWATH-MS data. Also, Professor Clive Orchard, University of Southampton, UK for his guidance on statistical analysis.

Funding
This work was supported by the Stoller Biomarker Discovery Centre (Manchester Academic Health Science Centre, University of Manchester, Manchester, UK) and Wessex Heart Surgery Fund (Southampton Hospital Charity, Mailpoint 135, Southampton General Hospital, Southampton, UK).

Availability of data and materials
The datasets generated and/or analysed during the current study are not publicly available due to further publications pending but are available from the corresponding author on reasonable request.

Authors’ contributions
OH designed the project, analysed the data and wrote the manuscript. FC designed the project and reviewed the manuscript. CT reviewed the manuscript. KS designed the project and reviewed the manuscript. SO designed the project, analysed the SWATH-MS data. Also, Professor Clive Orchard, University of Southampton, UK for his guidance on statistical analysis.

Ethics approval and consent to participate
This study complied with the declaration of Helsinki. Ethical approval was obtained from patients.

Consent for publication
Not applicable

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References
1. Basio C, Boschello M, Perrone C, Mecenero A, Cera A, Biggio D, Thieme G, De Dominici E. An echocardiographic survey of primary school children for bicuspid aortic valve. Am J Cardiol. 2004;93(5):661–3.
2. Movahed M-R, Hepner AD, Ahmad-Kashani M. Echocardiographic prevalence of bicuspid aortic valve in the population. Heart Lung Circ. 2006;15(5):297–9.
3. Della Corte A, Barcone C, Quarto C, DiLieto G, Covino FE, Scardone M, Cainello G, Cotrufo M. Predictors of ascending aortic dilatation with bicuspid aortic valve: a wide spectrum of disease expression. Eur J Cardiothorac Surg. 2007;31(3):397–404. discussion 404-395
4. Jackson V, Petini J, Caidahl K, Ericsson MJ, Liska J, Eriksson P, Franco-Cereceda A. Bicuspid aortic valve leafl et morphology in relation to aortic root morphology: a study of 300 patients undergoing open-heart surgery. Eur J Cardiothorac Surg. 2011;40(1):e118–24.
5. Verma S, Yagawara B, Kalla S, Ruel M, Peterson MD, Yamashita MH, Fagan A, Currie ME, White CW, Wai Sang SL, et al. Knowledge, attitudes, and practice patterns in surgical management of bicuspid aorticopathy: a survey of 100 cardiac surgeons. J Thorac Cardiovasc Surg. 2013;146(5):1033–40. e1034
6. Lee SH, Kim JB, Kim DH, Jung SH, Choo SJ, Chung CH, Lee JW. Management of dilated ascending aorta during aortic valve replacement: valve replacement alone versus aorta wrapping versus aorta replacement. J Thorac Cardiovasc Surg. 2013;146(4):802–9.
7. Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP 3rd, Fleisher LA, Gardin JM, Hijazi ZM, Jneid H, Mack MJ, McLeod CJ, O’Gara PT, et al. 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the Management of Patients with Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2017;70(2):252–89.
8. Becker RC. The investigation of biomarkers in cardiovascular disease: time for a coordinated, international effort. Eur Heart J. 2005;26(5):421–2.
9. Garbis SO, Townsend PA. Proteomics of human prostate cancer biospecimens: the global, systems-wide perspective for protein markers with potential clinical utility. Expert Rev Proteomics. 2013;10(4):337–54.
10. Ikonomidou JS, Ivey CR, Wheeler JB, Akerman AW, Rice A, Patel RK, Stroed RE, Shah AA, Hughes CG, Ferrari G, et al. Plasma biomarkers for distinguishing etiologic subtypes of thoracic aortic aneurysm disease. J Thorac Cardiovasc Surg. 2013;145(5):1326–33.
11. Tzemom LS, Lyseggien E, Silversides C, Jamorski M, Tong JH, Harvey P, Floros J, Su J. Endothelial function, carotid-femoral stiffness, and plasma matrix metalloproteinase-2 in men with bicuspid aortic valve and dilated aorta. J Am Coll Cardiol. 2010;55(7):660–8.
12. Drapiz S, Goraclzyk T, Jamka-Miszelski T, Olszewska M, Undas A. Nonstenotic bicuspid aortic valve is associated with elevated plasma asymmetric dimethylarginine. J Cardiovasc Med (Hagenton). 2013;14(6):446–52.
13. Klicklesmez KO, Abaci O, Kocas C, Yildiz A, Kaya A, Okcu B, Kuculkoglu S. Dilatation of the ascending aorta and serum alpha 1-antitrypsin level in patients with bicuspid aortic valve. Heart Vessel. 2012;27(4):391–7.
14. Wang Y, Wu B, Dong L, Wang C, Wang X, Shu X. Circulating matrix metalloproteinase patterns in association with aortic dilatation in bicuspid aortic valve patients with isolated severe aortic stenosis. Heart Vessel. 2016;31(2):189–97.
15. Alegret JM, Martinez-Micaelo N, Vernis JM, Ligeiro C, Palazon O, Valdivinos P, Tajes H, Beltran-Debon R. Circulating endothelial microparticles are elevated in bicuspid aortic valve disease and are associated to aortic root dilatation. Eur Heart J. 2015;36:552.
16. Shimada I, Rooney SJ, Pagano D, Farneti PA, Davies P, Guest PJ, Bonser RS. Prediction of thoracic aortic aneurysm expansion: validation of formulae describing growth. Ann Thorac Surg. 1999;67(6):1968–70. discussion 1979-1980

17. Gillot LC, Navarro P, Tate S, Rost H, Selevsek N, Reiter L, Bonner R, Aebersold R. Targeted data extraction of the MS/MS spectra generated by data-independent acquisition: a new concept for consistent and accurate proteome analysis. Mol Cell Proteomics. 2012;11(6):O111.016717.

18. Sievers HH, Schmidtko C, Klicksmez KD, Uner S, Kucukoglu S. Matrix metalloproteinase-2 and -9 levels in patients with dilated ascending aorta and bicuspid aortic valve. Echocardiography (Mount Kisco, NY). 2013;30(2):121–6.

19. Gillet LC, Navarro P, Tate S, Rost H, Selevsek N, Reiter L, Aebersold R. Targeted data extraction of the MS/MS spectra generated by data-independent acquisition: a new concept for consistent and accurate proteome analysis. Mol Cell Proteomics. 2012;11(6):O111.016717.

20. Giardina B, Messana R, Castagnola M. The multiple functions of hemoglobin. Crit Rev Biochem Mol Biol. 1995;30(3):165–96.

21. Martinez-Pinna R, Burillo E, Madrigal-Matute J, Lopez IA, Carnefero E, Torres-Fonseca MM, Llanas-Granda P, Eigo J, Michel J-B, Blanco-Colo LM, et al. Label-free proteomic analysis of red blood cell membrane fractions from abdominal aortic aneurysm patients. Proteomics Clin Appl. 2014;8(7–8):626–30.

22. Schmid F-X, Bielenberg K, Schneider A, Haussler A, Keyser A, Limbbaum D. Ascending aortic aneurysm associated with bicuspid and tricuspid aortic valve involvement and clinical relevance of smooth muscle cell apoptosis and expression of cell death-initiating proteins. Eur J Cardiothorac Surg. 2003;22(4):537–43.

23. Folkersen L, Wagster D, Paloschi V, Jackson V, Petrini J, Kurtovic S, Maleki S, Erikson MJ, Caidahl K, Hamsten A, et al. Unraveling divergent gene expression profiles in bicuspid and tricuspid aortic valve patients with thoracic aortic dilatation: the ASAP study. Mol Med. 2011;17(11–12):1365–73.

24. Grewal N, Gittenberger-de Groot AC, DeRuiter MC, Klaasz R, Poelmann RE, Duim S, Lindeman JHN, Koenraadt WMC, Mohamed SA, et al. Bicuspid aortic valve: phosphorylation of c-kit and downstream targets are prognostic for future aortopathy. Eur J Cardiothorac Surg. 2014;46(5):831–9.

25. de Sa M, Moshkovitz Y, Butany J, David TE. Histologic abnormalities of the ascending aorta and pulmonary trunk in patients with bicuspid aortic valve disease: clinical relevance to the Ross procedure. J Thorac Cardiovasc Surg. 1999;118(4):588–94.